US Cystic Fibrosis Market to Exceed $896 Million by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a strategic report on Cystic Fibrosis market in the US. The US market for cystic fibrosis (CF) is projected to exceed $896 million by 2015. Largely driven by the sales of two leading drugs, Pulmozyme and TOBI, the market is expected to further expand significantly over the coming years, given the successful launch of novel and enhanced drug formulations or therapies including new mucolytic drugs, pancreatic enzyme replacement drugs, anti-inflammatory drugs, and drugs targeting genetic CFTR defects.

Cystic Fibrosis: A US Market Report

Cystic fibrosis is one of the most common genetic disorders in the US. The US is home to about 30,000 cystic fibrosis patients, with more than 2,000 cases being diagnosed every year. Although improved approaches in symptomatic treatment over the years have increased the survival rate of patients, there exist no specific disease-modifying drug or drugs targeting the underlying cause of the disease or for curing the disease. Therapeutic interventions in addressing the underlying cause of cystic fibrosis continue to evolve, driven by the need for effective, cutting-edge intervention techniques that restore Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene function, while simultaneously ensuring patient comfort, and improving patients’ quality of life.

Pulmozyme and TOBI dominate the US market for Cystic Fibrosis drugs as stated by the new market research report on Cystic Fibrosis market. Pulmozyme® works by breaking up the thickened airway secretions, while TOBI® is an inhaled antibiotic indicated for the treatment of lung infections caused by Pseudomonas aeruginosa (Pa) in cystic fibrosis patients. However, Pulmozyme is facing stiff competition from hypertonic saline, which represents a cost-effective option of clearing sputum from the lungs of cystic fibrosis patients. The market is expected to further expand significantly over the coming years, given the successful launch of novel and promising enhanced drug formulations or therapies, including new mucolytic drugs, pancreatic enzyme replacement drugs, anti-inflammatory drugs, and drugs targeting genetic CFTR defects currently in pipeline.

Key players profiled in the report include Abbott Laboratories, Actelion Ltd., Axcan Pharma Inc., Digestive Care Inc., Eurand N.V., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Inspire Pharmaceuticals Inc., KaloBios Pharmaceuticals Inc., Nektar Therapeutics, Novartis AG, Pharmaxis Ltd., PTC Therapeutics Inc., Transave Inc., and Vertex Pharmaceuticals Inc.

The report titled “Cystic Fibrosis: A US Market Report” announced by Global Industry Analysts Inc., provides a comprehensive review on cystic fibrosis treatment, unmet medical needs, clinical pipeline, R&D initiatives, leading drugs, competitive scenario, clinical trials, product approvals, product introductions, recent industry activity, and coverage on key market participants worldwide. The study analyzes market data and analytics in terms of value sales for the United States.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Cystic_Fibrosis_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media